Leticia M. Wildner
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
Correction: A pragmatic pipeline for drug resistance and lineage identification in Mycobacterium tuberculosis using whole genome sequencing.
Journal: PLOS global public health
Published: August 21, 2025
Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB.
Journal: The Journal of antimicrobial chemotherapy
Published: March 03, 2025
Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial.
Journal: The Lancet. Infectious diseases
Published: December 06, 2024
Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial.
Journal: The Lancet. Infectious diseases
Published: December 06, 2024
Population pharmacokinetics and exposure-response relationship of the antituberculosis drug BTZ-043.
Population pharmacokinetics and exposure-response relationship of the antituberculosis drug BTZ-043.
Journal: The Journal of antimicrobial chemotherapy
Published: October 04, 2024
Unravelling the transcriptome of the human tuberculosis lesion and its clinical implications.
Journal: Nature communications
Published: May 16, 2024
A pragmatic pipeline for drug resistance and lineage identification in Mycobacterium tuberculosis using whole genome sequencing.
Journal: PLOS global public health
Published: December 20, 2023
Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043-02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial.
Journal: The Lancet. Microbe
Published: October 26, 2023
Thyroid hormone profile is related to prognosis in acute decompensation of cirrhosis.
Journal: Archives of endocrinology and metabolism
Published: July 01, 2023
A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis.
Journal: Trials
Published: September 01, 2022
Systemic Inflammatory Response Syndrome in Patients Hospitalized for Acute Decompensation of Cirrhosis.
Journal: Canadian journal of gastroenterology & hepatology
Published: February 02, 2021
Last Updated: 09/26/2026